SUNNYVALE, Calif. , Oct. 1, 2024 /PRNewswire/ -- Inflammatix, a pioneering molecular diagnostics company, today presented data demonstrating the high diagnostic and prognostic accuracy of the company's lead product, the TriVerityTM Test (TriVerity).
In an oral presentation at the 2024 Scientific Assembly of the American College of Emergency Physicians (ACEP24) in Las Vegas, Nev., Inflammatix researchers reported that the accuracy of TriVerity is not affected by the patient's immune status, an important consideration given the high risk of severe infection and sepsis among immunocompromised patients. "For emergency physicians, the pressure to accurately diagnose an individual with suspected infection is heightened when the patient is immunocompromised, as a misdiagnosis can have catastrophic consequences," said Sam Ajizian , MD, Chief Medical Officer at Inflammatix.
"Our data show that TriVerity yields diagnostic and prognostic results with a high degree of accuracy, regardless of the patient's immune status. Historical biomarkers in this space have demonstrated inferior performance with immunocompromised patients. The findings suggest that emergency physicians should be able to use TriVerity with great confidence when evaluating patients across the spectrum of diagnoses, severities, and comorbidities associated with acute infection or sepsis.
" Inflammatix researchers presented an interim analysis of data from the SEPSIS-SHIELD study (NCT04094818), a multicenter, prospective c.
